Newamsterdam Pharma Co NV

NewAmsterdam Pharma (NAMSW) delivers a 51.9% YTD rally by pioneering oral small‑molecule therapies for cardiovascular and metabolic diseases, promising long‑term growth despite current negative earnings.

NewAmsterdam Pharma Co NV has emerged as a potential game-changer in Alzheimer’s treatment with positive results from its BROADWAY clinical trial, offering a beacon of hope for millions affected by the disease.

NewAmsterdam Pharma Co NV has seen a surge in analyst confidence with two major financial institutions, Cantor Fitzgerald and RBC Capital, issuing positive ratings for the company’s stock.

Newamsterdam Pharma Co NV, a late-stage biopharmaceutical company, is set to present at the 2025 RBCCM Global Healthcare Conference, showcasing its oral small molecule therapies for cardiovascular and metabolic diseases.